{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:21:00Z","timestamp":1781536860716,"version":"3.54.5"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00417-025-06837-2","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:16:05Z","timestamp":1745813765000},"page":"2135-2148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Gene therapy in neovascular age related macular degeneration: an update"],"prefix":"10.1007","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-2511","authenticated-orcid":false,"given":"Erika","family":"Quesada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-1131","authenticated-orcid":false,"given":"Sof\u00eda","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6375-837X","authenticated-orcid":false,"given":"Xiomara","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-7058","authenticated-orcid":false,"given":"Lihteh","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"6837_CR1","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358:2606\u20132617","journal-title":"N Engl J Med"},{"key":"6837_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/iovs.62.14.26","volume":"62","author":"PA Campochiaro","year":"2021","unstructured":"Campochiaro PA (2021) Retinal and choroidal vascular diseases: past, present, and future: the 2021 proctor lecture. Invest Ophthalmol Vis Sci 62:26","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/phar.1264","volume":"33","author":"LK Cheung","year":"2013","unstructured":"Cheung LK, Eaton A (2013) Age-related macular degeneration. Pharmacotherapy 33:838\u2013855","journal-title":"Pharmacotherapy"},{"key":"6837_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2:1097\u20131105","journal-title":"Genes Cancer"},{"key":"6837_CR5","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","volume":"16","author":"JA Forsythe","year":"1996","unstructured":"Forsythe JA, Jiang BH, Iyer NV et al (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604\u20134613","journal-title":"Mol Cell Biol"},{"key":"6837_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00018-019-03422-9","volume":"77","author":"P Mammadzada","year":"2020","unstructured":"Mammadzada P, Corredoira PM, Andre H (2020) The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective. Cell Mol Life Sci 77:819\u2013833","journal-title":"Cell Mol Life Sci"},{"key":"6837_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/gt.2011.164","volume":"19","author":"PA Campochiaro","year":"2012","unstructured":"Campochiaro PA (2012) Gene transfer for ocular neovascularization and macular edema. Gene Ther 19:121\u2013126","journal-title":"Gene Ther"},{"key":"6837_CR8","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1167\/iovs.03-0862","volume":"45","author":"IA Bhutto","year":"2004","unstructured":"Bhutto IA, Kim SY, McLeod DS et al (2004) Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 45:1544\u20131552","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.exer.2005.05.007","volume":"82","author":"IA Bhutto","year":"2006","unstructured":"Bhutto IA, McLeod DS, Hasegawa T et al (2006) Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 82:99\u2013110","journal-title":"Exp Eye Res"},{"key":"6837_CR10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/archopht.126.5.670","volume":"126","author":"IA Bhutto","year":"2008","unstructured":"Bhutto IA, Uno K, Merges C et al (2008) Reduction of endogenous angiogenesis inhibitors in Bruch\u2019s membrane of the submacular region in eyes with age-related macular degeneration. Arch Ophthalmol 126:670\u2013678","journal-title":"Arch Ophthalmol"},{"key":"6837_CR11","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1042\/CS20170066","volume":"131","author":"M Farnoodian","year":"2017","unstructured":"Farnoodian M, Wang S, Dietz J et al (2017) Negative regulators of angiogenesis: important targets for treatment of exudative AMD. Clin Sci (Lond) 131:1763\u20131780","journal-title":"Clin Sci (Lond)"},{"key":"6837_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1126\/science.285.5425.245","volume":"285","author":"DW Dawson","year":"1999","unstructured":"Dawson DW, Volpert OV, Gillis P et al (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245\u2013248","journal-title":"Science"},{"key":"6837_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","volume":"88","author":"MS O\u2019Reilly","year":"1997","unstructured":"O\u2019Reilly MS, Boehm T, Shing Y et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277\u2013285","journal-title":"Cell"},{"key":"6837_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0002-9440(10)61697-5","volume":"159","author":"K Mori","year":"2001","unstructured":"Mori K, Ando A, Gehlbach P et al (2001) Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 159:313\u2013320","journal-title":"Am J Pathol"},{"key":"6837_CR15","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.4049\/jimmunol.161.12.6845","volume":"161","author":"LA Cornelius","year":"1998","unstructured":"Cornelius LA, Nehring LC, Harding E et al (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161:6845\u20136852","journal-title":"J Immunol"},{"key":"6837_CR16","doi-asserted-by":"publisher","first-page":"29568","DOI":"10.1074\/jbc.274.41.29568","volume":"274","author":"MS O\u2019Reilly","year":"1999","unstructured":"O\u2019Reilly MS, Wiederschain D, Stetler-Stevenson WG et al (1999) Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274:29568\u201329571","journal-title":"J Biol Chem"},{"key":"6837_CR17","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1073\/pnas.040378497","volume":"97","author":"A Pozzi","year":"2000","unstructured":"Pozzi A, Moberg PE, Miles LA et al (2000) Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A 97:2202\u20132207","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6837_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nm0696-689","volume":"2","author":"MS O\u2019Reilly","year":"1996","unstructured":"O\u2019Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689\u2013692","journal-title":"Nat Med"},{"key":"6837_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1101\/SQB.1994.059.01.052","volume":"59","author":"MS O\u2019Reilly","year":"1994","unstructured":"O\u2019Reilly MS, Holmgren L, Shing Y et al (1994) Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59:471\u2013482","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"6837_CR20","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1167\/iovs.16-19286","volume":"57","author":"MR Bohm","year":"2016","unstructured":"Bohm MR, Hodes F, Brockhaus K et al (2016) Is angiostatin involved in physiological foveal avascularity? Invest Ophthalmol Vis Sci 57:4536\u20134552","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR21","first-page":"3325","volume":"42","author":"TA Drixler","year":"2001","unstructured":"Drixler TA, Borel Rinkes IH, Ritchie ED et al (2001) Angiostatin inhibits pathological but not physiological retinal angiogenesis. Invest Ophthalmol Vis Sci 42:3325\u20133330","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1006\/bbrc.1996.1355","volume":"226","author":"RL Kendall","year":"1996","unstructured":"Kendall RL, Wang G, Thomas KA (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226:324\u2013328","journal-title":"Biochem Biophys Res Commun"},{"key":"6837_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100954","volume":"84","author":"A Uemura","year":"2021","unstructured":"Uemura A, Fruttiger M, D\u2019Amore PA et al (2021) VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res 84:100954","journal-title":"Prog Retin Eye Res"},{"key":"6837_CR24","doi-asserted-by":"publisher","unstructured":"(1993) Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials.Macular Photocoagulation Study Group. Arch Ophthalmol 111:1200\u20131209. https:\/\/doi.org\/10.1001\/archopht.1993.01090090052019","DOI":"10.1001\/archopht.1993.01090090052019"},{"key":"6837_CR25","doi-asserted-by":"crossref","unstructured":"(1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 117:1329\u20131345","DOI":"10.1001\/archopht.117.10.1329"},{"key":"6837_CR26","doi-asserted-by":"crossref","unstructured":"Kaiser PK, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study G (2006) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244:1132\u20131142","DOI":"10.1007\/s00417-005-0199-9"},{"key":"6837_CR27","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805\u20132816","journal-title":"N Engl J Med"},{"key":"6837_CR28","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"6837_CR29","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"6837_CR30","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1167\/iovs.04-0601","volume":"46","author":"J Gaudreault","year":"2005","unstructured":"Gaudreault J, Fei D, Rusit J et al (2005) Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726\u2013733","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121:193\u2013201","journal-title":"Ophthalmology"},{"key":"6837_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y et al (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72\u201384","journal-title":"Ophthalmology"},{"key":"6837_CR33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740","journal-title":"Lancet"},{"key":"6837_CR34","doi-asserted-by":"crossref","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388\u20131398","DOI":"10.1016\/j.ophtha.2012.03.053"},{"key":"6837_CR35","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","volume":"120","author":"L Kodjikian","year":"2013","unstructured":"Kodjikian L, Souied EH, Mimoun G et al (2013) Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 120:2300\u20132309","journal-title":"Ophthalmology"},{"key":"6837_CR36","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","volume":"119","author":"IS Investigators","year":"2012","unstructured":"Investigators IS, Chakravarthy U, Harding SP et al (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119:1399\u20131411","journal-title":"Ophthalmology"},{"key":"6837_CR37","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N et al (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393\u201311398","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6837_CR38","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"6837_CR39","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS et al (2024) Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403:1141\u20131152","journal-title":"Lancet"},{"key":"6837_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","volume":"128","author":"PU Dugel","year":"2021","unstructured":"Dugel PU, Singh RP, Koh A et al (2021) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128:89\u201399","journal-title":"Ophthalmology"},{"key":"6837_CR41","doi-asserted-by":"publisher","first-page":"1967714","DOI":"10.1080\/19420862.2021.1967714","volume":"13","author":"M Surowka","year":"2021","unstructured":"Surowka M, Schaefer W, Klein C (2021) Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. MAbs 13:1967714","journal-title":"MAbs"},{"key":"6837_CR42","doi-asserted-by":"crossref","unstructured":"Khanani AM, Kotecha A, Chang A et al (2024) TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology\u00a0131(8):914-926","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"6837_CR43","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1007\/s00417-021-05451-2","volume":"259","author":"P Lanzetta","year":"2021","unstructured":"Lanzetta P (2021) Anti-VEGF therapies for age-related macular degeneration: a powerful tactical gear or a blunt weapon? The choice is ours. Graefes Arch Clin Exp Ophthalmol 259:3561\u20133567","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6837_CR44","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.ophtha.2020.02.027","volume":"127","author":"S Kiss","year":"2020","unstructured":"Kiss S, Campbell J, Almony A et al (2020) Management and outcomes for neovascular age-related macular degeneration: analysis of United States electronic health records. Ophthalmology 127:1179\u20131188","journal-title":"Ophthalmology"},{"key":"6837_CR45","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/IAE.0000000000000827","volume":"36","author":"JF Arevalo","year":"2016","unstructured":"Arevalo JF, Lasave AF, Wu L et al (2016) Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the Pan-American Collaborative Retina Study Group. Retina 36:859\u2013867","journal-title":"Retina"},{"key":"6837_CR46","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy U, Havilio M, Syntosi A et al (2021) Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye (Lond) 35:2983\u20132990","journal-title":"Eye (Lond)"},{"key":"6837_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2021-000957","volume":"7","author":"V Sheth","year":"2022","unstructured":"Sheth V, D\u2019Rozario M, Gune S, Blotner S (2022) Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophthalmol 7:e000957","journal-title":"BMJ Open Ophthalmol"},{"key":"6837_CR48","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1159\/000539648","volume":"247","author":"B Pandya","year":"2024","unstructured":"Pandya B, Mihalache A, Hatamnejad A et al (2024) The association between retinal thickness fluctuations and visual outcomes under anti-vascular endothelial growth factor therapy: a systematic review and meta-analysis. Ophthalmologica 247:261\u2013274","journal-title":"Ophthalmologica"},{"key":"6837_CR49","doi-asserted-by":"crossref","unstructured":"Amato A, Arrigo A, Aragona E et al (2021) Gene therapy in inherited retinal diseases: an update on current state of the art. Front Med (Lausanne) 8:750586","DOI":"10.3389\/fmed.2021.750586"},{"key":"6837_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/bmb\/ldy005","volume":"126","author":"N Kumaran","year":"2018","unstructured":"Kumaran N, Michaelides M, Smith AJ et al (2018) Retinal gene therapy. Br Med Bull 126:13\u201325","journal-title":"Br Med Bull"},{"key":"6837_CR51","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/IAE.0000000000002197","volume":"38","author":"GY Cho","year":"2018","unstructured":"Cho GY, Schaefer KA, Bassuk AG et al (2018) Crispr genome surgery in the retina in light of off-targeting. Retina 38:1443\u20131455","journal-title":"Retina"},{"key":"6837_CR52","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA et al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390:849\u2013860","journal-title":"Lancet"},{"key":"6837_CR53","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","volume":"126","author":"AM Maguire","year":"2019","unstructured":"Maguire AM, Russell S, Wellman JA et al (2019) Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology 126:1273\u20131285","journal-title":"Ophthalmology"},{"key":"6837_CR54","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3928\/23258160-20230919-01","volume":"54","author":"A Sharma","year":"2023","unstructured":"Sharma A, Wu L, Bloom S et al (2023) RWC update: enhanced ILM peeling; retinal gene therapy; laser-induced retinal break and vitreous hemorrhage. Ophthalmic Surg Lasers Imaging Retina 54:564\u2013567","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"6837_CR55","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41433-021-01842-1","volume":"36","author":"AM Khanani","year":"2022","unstructured":"Khanani AM, Thomas MJ, Aziz AA et al (2022) Review of gene therapies for age-related macular degeneration. Eye (Lond) 36:303\u2013311","journal-title":"Eye (Lond)"},{"key":"6837_CR56","doi-asserted-by":"publisher","unstructured":"(1990) Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 108:816\u2013824. https:\/\/doi.org\/10.1001\/archopht.1990.01070080058036","DOI":"10.1001\/archopht.1990.01070080058036"},{"key":"6837_CR57","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.addr.2006.07.020","volume":"58","author":"E Fattal","year":"2006","unstructured":"Fattal E, Bochot A (2006) Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv Drug Deliv Rev 58:1203\u20131223","journal-title":"Adv Drug Deliv Rev"},{"key":"6837_CR58","doi-asserted-by":"crossref","unstructured":"Ramamoorth M, Narvekar A (2015) Non viral vectors in gene therapy- an overview. J Clin Diagn Res 9:GE01\u201306","DOI":"10.7860\/JCDR\/2015\/10443.5394"},{"key":"6837_CR59","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/424251b","volume":"424","author":"MA Kay","year":"2003","unstructured":"Kay MA, Nakai H (2003) Looking into the safety of AAV vectors. Nature 424:251","journal-title":"Nature"},{"key":"6837_CR60","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coph.2015.07.006","volume":"24","author":"L Lisowski","year":"2015","unstructured":"Lisowski L, Tay SS, Alexander IE (2015) Adeno-associated virus serotypes for gene therapeutics. Curr Opin Pharmacol 24:59\u201367","journal-title":"Curr Opin Pharmacol"},{"key":"6837_CR61","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.coviro.2016.07.010","volume":"21","author":"EM Everson","year":"2016","unstructured":"Everson EM, Trobridge GD (2016) Retroviral vector interactions with hematopoietic cells. Curr Opin Virol 21:41\u201346","journal-title":"Curr Opin Virol"},{"key":"6837_CR62","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/CMR.00008-08","volume":"21","author":"S Daya","year":"2008","unstructured":"Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21:583\u2013593","journal-title":"Clin Microbiol Rev"},{"key":"6837_CR63","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/biomedicines2010014","volume":"2","author":"A Shaw","year":"2014","unstructured":"Shaw A, Cornetta K (2014) Design and potential of non-integrating lentiviral vectors. Biomedicines 2:14\u201335","journal-title":"Biomedicines"},{"key":"6837_CR64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.visres.2007.07.027","volume":"48","author":"EM Surace","year":"2008","unstructured":"Surace EM, Auricchio A (2008) Versatility of AAV vectors for retinal gene transfer. Vision Res 48:353\u2013359","journal-title":"Vision Res"},{"key":"6837_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.oret.2017.09.015","volume":"2","author":"G Yiu","year":"2018","unstructured":"Yiu G (2018) Genome editing in retinal diseases using CRISPR technology. Ophthalmol Retina 2:1\u20133","journal-title":"Ophthalmol Retina"},{"key":"6837_CR66","doi-asserted-by":"crossref","unstructured":"Scarsella L, Ehrke-Schulz E, Paulussen M et al (2024) Advances of recombinant adenoviral vectors in preclinical and clinical applications. Viruses\u00a016(3):377","DOI":"10.3390\/v16030377"},{"key":"6837_CR67","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1073\/pnas.56.1.86","volume":"56","author":"JA Rose","year":"1966","unstructured":"Rose JA, Hoggan MD, Shatkin AJ (1966) Nucleic acid from an adeno-associated virus: chemical and physical studies. Proc Natl Acad Sci U S A 56:86\u201392","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6837_CR68","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL 3rd, Strohl WR (2017) Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31:317\u2013334","journal-title":"BioDrugs"},{"key":"6837_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100915","volume":"83","author":"K Bucher","year":"2021","unstructured":"Bucher K, Rodriguez-Bocanegra E, Dauletbekov D, Fischer MD (2021) Immune responses to retinal gene therapy using adeno-associated viral vectors - implications for treatment success and safety. Prog Retin Eye Res 83:100915","journal-title":"Prog Retin Eye Res"},{"key":"6837_CR70","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.4103\/1673-5374.306063","volume":"16","author":"M Ross","year":"2021","unstructured":"Ross M, Ofri R (2021) The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery. Neural Regen Res 16:1751\u20131759","journal-title":"Neural Regen Res"},{"key":"6837_CR71","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/pharmaceutics14081605","volume":"14","author":"Y Arsenijevic","year":"2022","unstructured":"Arsenijevic Y, Berger A, Udry F, Kostic C (2022) Lentiviral vectors for ocular gene therapy. Pharmaceutics 14:1605","journal-title":"Pharmaceutics"},{"key":"6837_CR72","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1128\/JVI.75.7.3371-3382.2001","volume":"75","author":"R Berkowitz","year":"2001","unstructured":"Berkowitz R, Ilves H, Lin WY et al (2001) Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus. J Virol 75:3371\u20133382","journal-title":"J Virol"},{"key":"6837_CR73","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nm1365","volume":"12","author":"RJ Yanez-Munoz","year":"2006","unstructured":"Yanez-Munoz RJ, Balaggan KS, MacNeil A et al (2006) Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 12:348\u2013353","journal-title":"Nat Med"},{"key":"6837_CR74","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/sj.gt.3301023","volume":"6","author":"K Mitrophanous","year":"1999","unstructured":"Mitrophanous K, Yoon S, Rohll J et al (1999) Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 6:1808\u20131818","journal-title":"Gene Ther"},{"key":"6837_CR75","doi-asserted-by":"publisher","first-page":"189ra176","DOI":"10.1126\/scitranslmed.3005708","volume":"5","author":"D Dalkara","year":"2013","unstructured":"Dalkara D, Byrne LC, Klimczak RR et al (2013) In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 5:189ra176","journal-title":"Sci Transl Med"},{"key":"6837_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/APO.0000000000000362","volume":"10","author":"D Xu","year":"2021","unstructured":"Xu D, Khan MA, Ho AC (2021) Creating an ocular biofactory: surgical approaches in gene therapy for acquired retinal diseases. Asia Pac J Ophthalmol (Phila) 10:5\u201311","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"6837_CR77","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1172\/JCI129085","volume":"129","author":"K Ding","year":"2019","unstructured":"Ding K, Shen J, Hafiz Z et al (2019) AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. J Clin Invest 129:4901\u20134911","journal-title":"J Clin Invest"},{"key":"6837_CR78","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/hum.1998.9.1-81","volume":"9","author":"RR Ali","year":"1998","unstructured":"Ali RR, Reichel MB, De Alwis M et al (1998) Adeno-associated virus gene transfer to mouse retina. Hum Gene Ther 9:81\u201386","journal-title":"Hum Gene Ther"},{"key":"6837_CR79","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1089\/10430349950018715","volume":"10","author":"F Rolling","year":"1999","unstructured":"Rolling F, Shen WY, Tabarias H et al (1999) Evaluation of adeno-associated virus-mediated gene transfer into the rat retina by clinical fluorescence photography. Hum Gene Ther 10:641\u2013648","journal-title":"Hum Gene Ther"},{"key":"6837_CR80","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1016\/S0042-6989(98)00308-3","volume":"39","author":"L Dudus","year":"1999","unstructured":"Dudus L, Anand V, Acland GM et al (1999) Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res 39:2545\u20132553","journal-title":"Vision Res"},{"key":"6837_CR81","first-page":"2857","volume":"38","author":"J Bennett","year":"1997","unstructured":"Bennett J, Duan D, Engelhardt JF, Maguire AM (1997) Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. Invest Ophthalmol Vis Sci 38:2857\u20132863","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR82","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1073\/pnas.94.13.6916","volume":"94","author":"JG Flannery","year":"1997","unstructured":"Flannery JG, Zolotukhin S, Vaquero MI et al (1997) Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A 94:6916\u20136921","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6837_CR83","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/gt.2011.153","volume":"19","author":"KS Balaggan","year":"2012","unstructured":"Balaggan KS, Ali RR (2012) Ocular gene delivery using lentiviral vectors. Gene Ther 19:145\u2013153","journal-title":"Gene Ther"},{"key":"6837_CR84","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/jop.2019.0126","volume":"36","author":"V Kansara","year":"2020","unstructured":"Kansara V, Muya L, Wan CR, Ciulla TA (2020) Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases. J Ocul Pharmacol Ther 36:384\u2013392","journal-title":"J Ocul Pharmacol Ther"},{"key":"6837_CR85","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/IAE.0000000000004087","volume":"44","author":"CC Wykoff","year":"2024","unstructured":"Wykoff CC, Avery RL, Barakat MR et al (2024) Suprachoroidal space injection technique: expert panel guidance. Retina 44:939\u2013949","journal-title":"Retina"},{"key":"6837_CR86","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/1566523052997514","volume":"5","author":"Y Yi","year":"2005","unstructured":"Yi Y, Hahm SH, Lee KH (2005) Retroviral gene therapy: safety issues and possible solutions. Curr Gene Ther 5:25\u201335","journal-title":"Curr Gene Ther"},{"key":"6837_CR87","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","volume":"80","author":"SE Raper","year":"2003","unstructured":"Raper SE, Chirmule N, Lee FS et al (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148\u2013158","journal-title":"Mol Genet Metab"},{"key":"6837_CR88","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ymgme.2008.12.016","volume":"96","author":"JM Wilson","year":"2009","unstructured":"Wilson JM (2009) Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab 96:151\u2013157","journal-title":"Mol Genet Metab"},{"key":"6837_CR89","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1126\/science.288.5466.669","volume":"288","author":"M Cavazzana-Calvo","year":"2000","unstructured":"Cavazzana-Calvo M, Hacein-Bey S, de Saint BG et al (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669\u2013672","journal-title":"Science"},{"key":"6837_CR90","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1126\/science.299.5606.495","volume":"299","author":"J Kaiser","year":"2003","unstructured":"Kaiser J (2003) Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science 299:495","journal-title":"Science"},{"key":"6837_CR91","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nrc1122","volume":"3","author":"DB Kohn","year":"2003","unstructured":"Kohn DB, Sadelain M, Glorioso JC (2003) Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 3:477\u2013488","journal-title":"Nat Rev Cancer"},{"key":"6837_CR92","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3109\/09273948.2010.512696","volume":"18","author":"J Hori","year":"2010","unstructured":"Hori J, Vega JL, Masli S (2010) Review of ocular immune privilege in the year 2010: modifying the immune privilege of the eye. Ocul Immunol Inflamm 18:325\u2013333","journal-title":"Ocul Immunol Inflamm"},{"key":"6837_CR93","doi-asserted-by":"crossref","unstructured":"Weyand CM, Goronzy JJ (2016) Aging of the immune system. Mechanisms and therapeutic targets. Ann Am Thorac Soc 13 Suppl 5:S422-S428","DOI":"10.1513\/AnnalsATS.201602-095AW"},{"key":"6837_CR94","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","volume":"16","author":"J Zhou","year":"2017","unstructured":"Zhou J, Rossi J (2017) Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov 16:181\u2013202","journal-title":"Nat Rev Drug Discov"},{"key":"6837_CR95","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/14728214.2017.1362390","volume":"22","author":"RM Hussain","year":"2017","unstructured":"Hussain RM, Ciulla TA (2017) Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert Opin Emerg Drugs 22:235\u2013246","journal-title":"Expert Opin Emerg Drugs"},{"key":"6837_CR96","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3928\/23258160-20170130-02","volume":"48","author":"EN Dunn","year":"2017","unstructured":"Dunn EN, Hariprasad SM, Sheth VS (2017) An overview of the fovista and Rinucumab trials and the fate of anti-PDGF medications. Ophthalmic Surg Lasers Imaging Retina 48:100\u2013104","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"6837_CR97","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2165\/00003088-200241040-00002","volume":"41","author":"RS Geary","year":"2002","unstructured":"Geary RS, Henry SP, Grillone LR (2002) Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet 41:255\u2013260","journal-title":"Clin Pharmacokinet"},{"key":"6837_CR98","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1167\/iovs.11-9064","volume":"53","author":"F Cloutier","year":"2012","unstructured":"Cloutier F, Lawrence M, Goody R et al (2012) Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration. Invest Ophthalmol Vis Sci 53:1195\u20131203","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR99","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806\u2013811","journal-title":"Nature"},{"key":"6837_CR100","doi-asserted-by":"publisher","first-page":"15502","DOI":"10.1073\/pnas.95.26.15502","volume":"95","author":"MK Montgomery","year":"1998","unstructured":"Montgomery MK, Xu S, Fire A (1998) RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci U S A 95:15502\u201315507","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6837_CR101","first-page":"253","volume":"43","author":"A Bochot","year":"2002","unstructured":"Bochot A, Fattal E, Boutet V et al (2002) Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci 43:253\u2013259","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR102","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1261\/rna.5205404","volume":"10","author":"DE Draper","year":"2004","unstructured":"Draper DE (2004) A guide to ions and RNA structure. RNA 10:335\u2013343","journal-title":"RNA"},{"key":"6837_CR103","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/IAE.0b013e3181ad2341","volume":"29","author":"L Singerman","year":"2009","unstructured":"Singerman L (2009) Combination therapy using the small interfering RNA bevasiranib. Retina 29:S49-50","journal-title":"Retina"},{"key":"6837_CR104","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature06765","volume":"452","author":"ME Kleinman","year":"2008","unstructured":"Kleinman ME, Yamada K, Takeda A et al (2008) Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452:591\u2013597","journal-title":"Nature"},{"key":"6837_CR105","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4137\/OED.S4878","volume":"2","author":"AO Garba","year":"2010","unstructured":"Garba AO, Mousa SA (2010) Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis 2:75\u201383","journal-title":"Ophthalmol Eye Dis"},{"key":"6837_CR106","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.gt.3302641","volume":"13","author":"J Shen","year":"2006","unstructured":"Shen J, Samul R, Silva RL et al (2006) Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 13:225\u2013234","journal-title":"Gene Ther"},{"key":"6837_CR107","doi-asserted-by":"crossref","unstructured":"Kaiser PK, Symons RC, Shah SM et al (2010) RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 150:33\u201339 e32","DOI":"10.1016\/j.ajo.2010.02.006"},{"key":"6837_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2021.108482","volume":"205","author":"A Gupta","year":"2021","unstructured":"Gupta A, Kafetzis KN, Tagalakis AD, Yu-Wai-Man C (2021) RNA therapeutics in ophthalmology - translation to clinical trials. Exp Eye Res 205:108482","journal-title":"Exp Eye Res"},{"key":"6837_CR109","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/eye.2012.106","volume":"26","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Schachar RA, Nduaka CI et al (2012) Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (Lond) 26:1099\u20131105","journal-title":"Eye (Lond)"},{"key":"6837_CR110","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.ophtha.2012.03.043","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Schachar RA, Nduaka CI et al (2012) Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology 119:1867\u20131873","journal-title":"Ophthalmology"},{"key":"6837_CR111","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jcp.1114","volume":"188","author":"K Mori","year":"2001","unstructured":"Mori K, Duh E, Gehlbach P et al (2001) Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 188:253\u2013263","journal-title":"J Cell Physiol"},{"key":"6837_CR112","first-page":"2428","volume":"43","author":"K Mori","year":"2002","unstructured":"Mori K, Gehlbach P, Ando A et al (2002) Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 43:2428\u20132434","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR113","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/hum.2006.17.167","volume":"17","author":"PA Campochiaro","year":"2006","unstructured":"Campochiaro PA, Nguyen QD, Shah SM et al (2006) Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 17:167\u2013176","journal-title":"Hum Gene Ther"},{"key":"6837_CR114","first-page":"2401","volume":"42","author":"CC Lai","year":"2001","unstructured":"Lai CC, Wu WC, Chen SL et al (2001) Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest Ophthalmol Vis Sci 42:2401\u20132407","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR115","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1096\/fj.07-8422com","volume":"21","author":"AG Marneros","year":"2007","unstructured":"Marneros AG, She H, Zambarakji H et al (2007) Endogenous endostatin inhibits choroidal neovascularization. FASEB J 21:3809\u20133818","journal-title":"FASEB J"},{"key":"6837_CR116","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1089\/hum.2012.008","volume":"23","author":"K Binley","year":"2012","unstructured":"Binley K, Widdowson PS, Kelleher M et al (2012) Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat((R)), for age-related macular degeneration. Hum Gene Ther 23:980\u2013991","journal-title":"Hum Gene Ther"},{"key":"6837_CR117","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1089\/hum.2016.117","volume":"28","author":"PA Campochiaro","year":"2017","unstructured":"Campochiaro PA, Lauer AK, Sohn EH et al (2017) Lentiviral vector gene transfer of endostatin\/angiostatin for macular degeneration (GEM) study. Hum Gene Ther 28:99\u2013111","journal-title":"Hum Gene Ther"},{"key":"6837_CR118","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/sj.gt.3301203","volume":"7","author":"M Honda","year":"2000","unstructured":"Honda M, Sakamoto T, Ishibashi T et al (2000) Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF\/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther 7:978\u2013985","journal-title":"Gene Ther"},{"key":"6837_CR119","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1089\/104303401750270959","volume":"12","author":"CM Lai","year":"2001","unstructured":"Lai CM, Brankov M, Zaknich T et al (2001) Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 12:1299\u20131310","journal-title":"Hum Gene Ther"},{"key":"6837_CR120","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1089\/104303403321070829","volume":"14","author":"P Gehlbach","year":"2003","unstructured":"Gehlbach P, Demetriades AM, Yamamoto S et al (2003) Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther 14:129\u2013141","journal-title":"Hum Gene Ther"},{"key":"6837_CR121","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/sj.gt.3301680","volume":"9","author":"JW Bainbridge","year":"2002","unstructured":"Bainbridge JW, Mistry A, De Alwis M et al (2002) Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 9:320\u2013326","journal-title":"Gene Ther"},{"key":"6837_CR122","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/sj.gt.3301695","volume":"9","author":"YK Lai","year":"2002","unstructured":"Lai YK, Shen WY, Brankov M et al (2002) Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther 9:804\u2013813","journal-title":"Gene Ther"},{"key":"6837_CR123","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ymthe.2005.04.022","volume":"12","author":"CM Lai","year":"2005","unstructured":"Lai CM, Shen WY, Brankov M et al (2005) Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 12:659\u2013668","journal-title":"Mol Ther"},{"key":"6837_CR124","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","volume":"386","author":"EP Rakoczy","year":"2015","unstructured":"Rakoczy EP, Lai CM, Magno AL et al (2015) Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet 386:2395\u20132403","journal-title":"Lancet"},{"key":"6837_CR125","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2017.02.018","volume":"177","author":"IJ Constable","year":"2017","unstructured":"Constable IJ, Lai CM, Magno AL et al (2017) Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a phase 1 randomized dose escalation trial. Am J Ophthalmol 177:150\u2013158","journal-title":"Am J Ophthalmol"},{"key":"6837_CR126","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/APO.0000000000000222","volume":"5","author":"IJ Constable","year":"2016","unstructured":"Constable IJ, Blumenkranz MS, Schwartz SD et al (2016) Gene therapy for age-related macular degeneration. Asia Pac J Ophthalmol (Phila) 5:300\u2013303","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"6837_CR127","doi-asserted-by":"crossref","unstructured":"Constable IJ, Pierce CM, Lai CM et al (2016) Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine 14:168\u2013175","DOI":"10.1016\/j.ebiom.2016.11.016"},{"key":"6837_CR128","doi-asserted-by":"crossref","unstructured":"Rakoczy EP, Magno AL, Lai CM et al (2019) Three-year follow-up of phase 1 and 2a rAAV.sFLT-1 subretinal gene therapy trials for exudative age-related macular degeneration. Am J Ophthalmol 204:113\u2013123","DOI":"10.1016\/j.ajo.2019.03.006"},{"key":"6837_CR129","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","volume":"390","author":"JS Heier","year":"2017","unstructured":"Heier JS, Kherani S, Desai S et al (2017) Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet 390:50\u201361","journal-title":"Lancet"},{"key":"6837_CR130","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1089\/jop.2021.0001","volume":"37","author":"CM Gelfman","year":"2021","unstructured":"Gelfman CM, Grishanin R, Bender KO et al (2021) Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema. J Ocul Pharmacol Ther 37:181\u2013190","journal-title":"J Ocul Pharmacol Ther"},{"key":"6837_CR131","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1167\/tvst.10.1.34","volume":"10","author":"S Kiss","year":"2021","unstructured":"Kiss S, Oresic Bender K, Grishanin RN et al (2021) Long-term safety evaluation of continuous intraocular delivery of Aflibercept by the intravitreal gene therapy candidate ADVM-022 in nonhuman primates. Transl Vis Sci Technol 10:34","journal-title":"Transl Vis Sci Technol"},{"key":"6837_CR132","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","volume":"27","author":"R Grishanin","year":"2019","unstructured":"Grishanin R, Vuillemenot B, Sharma P et al (2019) Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration. Mol Ther 27:118\u2013129","journal-title":"Mol Ther"},{"key":"6837_CR133","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.omtm.2020.06.007","volume":"18","author":"S Kiss","year":"2020","unstructured":"Kiss S, Grishanin R, Nguyen A et al (2020) Analysis of Aflibercept expression in NHPs following intravitreal administration of ADVM-022, a potential gene therapy for nAMD. Mol Ther Methods Clin Dev 18:345\u2013353","journal-title":"Mol Ther Methods Clin Dev"},{"key":"6837_CR134","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1167\/iovs.15-16418","volume":"56","author":"N Celik","year":"2015","unstructured":"Celik N, Scheuerle A, Auffarth GU et al (2015) Intraocular pharmacokinetics of Aflibercept and vascular endothelial growth factor-A. Invest Ophthalmol Vis Sci 56:5574\u20135578","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102394","volume":"67","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Boyer DS, Wykoff CC et al (2024) Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study. EClinicalMedicine 67:102394","journal-title":"EClinicalMedicine"},{"key":"6837_CR136","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","volume":"403","author":"PA Campochiaro","year":"2024","unstructured":"Campochiaro PA, Avery R, Brown DM et al (2024) Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study. Lancet 403:1563\u20131573","journal-title":"Lancet"},{"key":"6837_CR137","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/17425247.2024.2435461","volume":"21","author":"TA Ciulla","year":"2024","unstructured":"Ciulla TA, Cunningham ET Jr (2024) Suprachoroidal drug delivery: a versatile therapeutic platform. Expert Opin Drug Deliv 21:1705\u20131713","journal-title":"Expert Opin Drug Deliv"},{"key":"6837_CR138","doi-asserted-by":"crossref","unstructured":"Rowe LW, Ciulla TA (2024) Gene therapy for non-hereditary retinal disease: age-related macular degeneration, diabetic retinopathy, and beyond. Genes (Basel) 15:720","DOI":"10.3390\/genes15060720"},{"key":"6837_CR139","doi-asserted-by":"publisher","first-page":"14500","DOI":"10.1038\/ncomms14500","volume":"8","author":"E Kim","year":"2017","unstructured":"Kim E, Koo T, Park SW et al (2017) In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat Commun 8:14500","journal-title":"Nat Commun"},{"key":"6837_CR140","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1167\/iovs.16-20296","volume":"57","author":"G Yiu","year":"2016","unstructured":"Yiu G, Tieu E, Nguyen AT et al (2016) Genomic disruption of VEGF-A expression in human retinal pigment epithelial cells using CRISPR-Cas9 endonuclease. Invest Ophthalmol Vis Sci 57:5490\u20135497","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR141","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.1038\/s41598-023-29014-z","volume":"13","author":"J Park","year":"2023","unstructured":"Park J, Cui G, Lee H et al (2023) CRISPR\/Cas9 mediated specific ablation of vegfa in retinal pigment epithelium efficiently regresses choroidal neovascularization. Sci Rep 13:3715","journal-title":"Sci Rep"},{"key":"6837_CR142","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41467-017-00140-3","volume":"8","author":"X Huang","year":"2017","unstructured":"Huang X, Zhou G, Wu W et al (2017) Genome editing abrogates angiogenesis in vivo. Nat Commun 8:112","journal-title":"Nat Commun"},{"key":"6837_CR143","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1167\/iovs.17-21902","volume":"58","author":"W Wu","year":"2017","unstructured":"Wu W, Duan Y, Ma G et al (2017) AAV-CRISPR\/Cas9-mediated depletion of VEGFR2 blocks angiogenesis in vitro. Invest Ophthalmol Vis Sci 58:6082\u20136090","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR144","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1167\/iovs.16-20537","volume":"58","author":"X Huang","year":"2017","unstructured":"Huang X, Zhou G, Wu W et al (2017) Editing VEGFR2 blocks VEGF-induced activation of akt and tube formation. Invest Ophthalmol Vis Sci 58:1228\u20131236","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6837_CR145","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/s41467-018-04175-y","volume":"9","author":"T Koo","year":"2018","unstructured":"Koo T, Park SW, Jo DH et al (2018) CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration. Nat Commun 9:1855","journal-title":"Nat Commun"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06837-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06837-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06837-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:40:23Z","timestamp":1757259623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06837-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":145,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6837"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06837-2","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Erika Quesada MD, Sof\u00eda Rojas MD and Xiomara Campos MD have no competing interests to declare that are relevant to the content of this article. Furthermore they have no relevant financial or non-financial interests to disclose.Lihteh Wu MD has received lecture and consultant fees from Bayer, Roche, Lumibird Medical, Iveric Bio and Apellis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}